Inactive Instrument

Abcam plc

ABCM

US0003802040

Abcam plc Provides Earnings Guidance for the Year 2023 and Reiterates Earnings Guidance for the Year 2024

March 20, 2023 at 07:05 am EDT

Abcam plc provided earnings guidance for the year 2023 and reiterated earnings guidance for the year 2024. For the year 2023, the company anticipated reported revenues of approximately £420 million to £440 million, representing 15% to 20% constant exchange rate revenue growth.

The Company is reiterating its 2024 revenue goals of £450 million to £525 million.

Latest news about Abcam plc

Global markets live: Mastercard, Diageo, Nvidia, Airbnb, Exxon Mobil...	Dec. 06
Job losses delight investors	Dec. 06
Danaher Closes Acquisition of Abcam	Dec. 06	MT
Danaher completes $5.7 billion acquisition of Abcam	Dec. 06	RE
Abcam plc(NasdaqGS:ABCM) dropped from NASDAQ Composite Index	Dec. 06	CI
Abcam plc(NasdaqGS:ABCM) dropped from NASDAQ Biotechnology Index	Dec. 06	CI
Abcam plc(NasdaqGS:ABCM) dropped from S&P Global BMI Index	Dec. 06	CI
Danaher Corporation completed the acquisition of Abcam plc.	Dec. 05	CI
Abcam's Acquisition by Danaher Approved by UK Court	Dec. 04	MT
Abcam Says All Necessary Clearances for Acquisition by Danaher Obtained; Deal Set to be Completed on Dec. 6	Nov. 17	MT
All good things must come to an end	Nov. 07
Abcam Shareholders Approve Danaher's Acquisition Offer	Nov. 06	MT
Abcam shareholders approve $5.7 billion Danaher deal	Nov. 06	RE
Jonathan Milner Suspends his Vote Against Campaign	Nov. 01	CI
RBC Trims Price Target on Abcam to $24 From $25, Keeps Sector Perform Rating	23-10-31	MT
Jonathan Milner Issues Statement Responding to the Glass Lewis Report	23-10-23	CI
Jonathan Milner Continues Opposition to Danaher Corporation Acquisition	23-10-18	CI
Institutional Shareholder Services Recommends Shareholders Vote for Danaher Corporation?s Proposed Acquisition of Abcam plc	23-10-17	CI
Jonathan Milner Releases Presentation to Abcam plc Shareholders	23-10-16	CI
Jonathan Milner issues Open Letter to shareholders of Abcam plc	23-10-10	CI
Abcam Sends Letter Seeking Shareholders' Approval of Danaher's Takeover Offer	23-10-05	MT
Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher	23-10-05	CI
Jonathan Milner issues Open Letter to Shareholders of Abcam plc	23-09-28	CI
Abcam founder says he will vote against $5.7 billion Danaher deal	23-09-14	RE
Abcam founder Jonathan Milner opposes Danaher deal	23-09-14	RE

Chart Abcam plc

Duration

Period

More charts

Company Profile

Abcam plc is a global life science company. The Company serves customers at the forefront of life science research through the identification, development, and distribution of biological reagents. Its products are used by researchers around the world to study biological pathways critical for scientific research, diagnostics, and drug discovery. It offers a selection of products in its catalogue to support research on proteins in biological pathways. Its principal catalogue product lines include primary and secondary antibodies, conjugated antibodies and conjugation kits, and singleplex immunoassays. It offers a range of peptides and proteins, which include cytokines, growth factors, and enzymes. It offers a range of knockout cell lines and lysates, which are used for its in-house validation needs and are also made available to its customers for their own research. It offers a variety of other products, including cellular activity kits, biochemicals and cell signaling pathway tools.

Sector

Pharmaceuticals

Calendar

2024-09-08 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-15.94%	31.67B
UCB	+52.66%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.65B
INCYTE CORPORATION	-14.38%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.81B
INNOVENT BIOLOGICS, INC.	-4.33%	8.5B

Biopharmaceuticals